Fiscally responsible mindset to develop corporate value in early-stage development process, build and communicate business acumen, foster collaboration and teamwork among staff through engagement and coaching to develop teams that deliver results. Well versed in agency interactions from writing product characterization, manufacturing and controls technical section submissions as well as leading technical aspects of pre-approval and licensure audit inspections. Responsible for meeting growth requirements as well as assisting with strategic, regulatory, clinical, and scientific functions. Known for streamlining operations through reengineering and building highly skilled and motivated teams to deliver strong business results. Excellent track record in partnering with top management and driving strategic value creation. Wrightson is a proven Chief Operating/Technical Officer with over 25 years’ successful leadership experience in scientific and technical operations, and research and development in the regenerative medicine, protein expression and genomic diagnostics industries for both human and veterinary markets. Black holds a DVM from University of Wisconsin-Madison, a PhD in Cell and Molecular Biology from University of Pennsylvania School of Medicine, and completed her post-doctoral fellowship at GlaxoSmithKline. She is a member of the scientific advisory boards of Medicus Biosciences and Zander Therapeutics, and a member of the board of Directors for Gallant. Black consulted exclusively for Merial, Ltd, now Boehringer Ingelheim Animal Health, supporting R&D, marketing, and sales divisions. She was the founder and CEO of SciStem Therapeutics, a company focused on delivering off-the-shelf genetically modified stem cells for bone healing in pets and people. This culminated with leading a product development team to develop the first “off-the-shelf “stem cell therapies for dogs with osteoarthritis, which was later licensed to Aratana.
She authored the first peer reviewed publications describing the safety and efficacy of primary adipose-derived stem cells in osteoarthritis and muscle injury in working dogs. Prior to Medicus, she served as the VP of Product Development for VetStem Biopharma, the first veterinary stem cell company to provide regenerative therapies to horses, dogs and cats. She has led corporate development, finance, operations, and R&D along with a track record in regenerative medicine – with extensive experience in the development and commercialization of stem cell therapies for pets.įrom 2016 to 2019, she served as President and Chief Scientific Officer at Medicus Biosciences, a preclinical biotech firm focused on using polymer technologies for localized drug and stem cell delivery. She brings over 17 years of cross-functional experience leading strategic and operational initiatives in the biotechnology industry. Black started with Gallant in 2019 and served as President and Chief Scientific Officer before moving to Chief Executive Officer in April 2021. Gallant is determined more than ever to carry on his legacy, and we will remain true to his mission and vision. We are deeply saddened, and he will forever be missed. He was on several private company boards, a member of YPO, an angel investor, and was a 2016 finalist for E&Y entrepreneur of the year. Prior to this, he worked at Monitor Group and Kayne Anderson Capital.
Outside of Gallant, Aaron was a Venture Partner at Bold Capital and previously served as a venture investor with Upfront Ventures.
The business merged with Rover () in April 2017 to create what is now a $1B pet services company. DogVacay raised $47m from investors including Benchmark Capital and Andreessen Horowitz. Previously, Aaron was the founder and CEO of DogVacay, a consumer marketplace app for dog sitting and dog walking. Inspired by the impact of regenerative medicine on his own life, Aaron founded Gallant in mid-2018. As the founder of Gallant, Aaron Hirschhorn brought 20 years of experience operating, advising, and investing in technology companies.
0 kommentar(er)
